97 related articles for article (PubMed ID: 1862765)
1. Dose-related alpha-difluoromethylornithine ototoxicity.
Croghan MK; Aickin MG; Meyskens FL
Am J Clin Oncol; 1991 Aug; 14(4):331-5. PubMed ID: 1862765
[TBL] [Abstract][Full Text] [Related]
2. alpha-difluoromethylornithine ototoxicity. Chemoprevention clinical trial results.
Pasic TR; Heisey D; Love RR
Arch Otolaryngol Head Neck Surg; 1997 Dec; 123(12):1281-6. PubMed ID: 9413354
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.
McLaren CE; Fujikawa-Brooks S; Chen WP; Gillen DL; Pelot D; Gerner EW; Meyskens FL
Cancer Prev Res (Phila); 2008 Dec; 1(7):514-21. PubMed ID: 19139001
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of alpha-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma.
Meyskens FL; Kingsley EM; Glattke T; Loescher L; Booth A
Invest New Drugs; 1986; 4(3):257-62. PubMed ID: 3102397
[TBL] [Abstract][Full Text] [Related]
5. Effects of difluoromethylornithine chemoprevention on audiometry thresholds and otoacoustic emissions.
Doyle KJ; McLaren CE; Shanks JE; Galus CM; Meyskens FL
Arch Otolaryngol Head Neck Surg; 2001 May; 127(5):553-8. PubMed ID: 11346432
[TBL] [Abstract][Full Text] [Related]
6. Carboplatin is ototoxic.
Kennedy IC; Fitzharris BM; Colls BM; Atkinson CH
Cancer Chemother Pharmacol; 1990; 26(3):232-4. PubMed ID: 2192812
[TBL] [Abstract][Full Text] [Related]
7. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention.
Meyskens FL; Gerner EW; Emerson S; Pelot D; Durbin T; Doyle K; Lagerberg W
J Natl Cancer Inst; 1998 Aug; 90(16):1212-8. PubMed ID: 9719082
[TBL] [Abstract][Full Text] [Related]
8. A phase I trial of recombinant interferon-alpha and alpha-difluoromethylornithine in metastatic melanoma.
Croghan MK; Booth A; Meyskens FL
J Biol Response Mod; 1988 Aug; 7(4):409-15. PubMed ID: 3139843
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin ototoxicity: the importance of baseline audiometry.
Nagy JL; Adelstein DJ; Newman CW; Rybicki LA; Rice TW; Lavertu P
Am J Clin Oncol; 1999 Jun; 22(3):305-8. PubMed ID: 10362343
[TBL] [Abstract][Full Text] [Related]
10. Ototoxicity of Long-Term α-Difluoromethylornithine for Skin Cancer Prevention.
Chow CL; Havighurst T; Lozar T; Jones TD; Kim K; Bailey HH
Laryngoscope; 2023 Mar; 133(3):676-682. PubMed ID: 35620919
[TBL] [Abstract][Full Text] [Related]
11. Irreversible ototoxicity associated with difluoromethylornithine.
Lao CD; Backoff P; Shotland LI; McCarty D; Eaton T; Ondrey FG; Viner JL; Spechler SJ; Hawk ET; Brenner DE
Cancer Epidemiol Biomarkers Prev; 2004 Jul; 13(7):1250-2. PubMed ID: 15247138
[TBL] [Abstract][Full Text] [Related]
12. Difluoromethylornithine and leukocyte interferon: a phase I study in cancer patients.
Talpaz M; Plager C; Quesada J; Benjamin R; Kantarjian H; Gutterman J
Eur J Cancer Clin Oncol; 1986 Jun; 22(6):685-9. PubMed ID: 3091371
[TBL] [Abstract][Full Text] [Related]
13. Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials.
Loprinzi CL; Messing EM; O'Fallon JR; Poon MA; Love RR; Quella SK; Trump DL; Morton RF; Novotny P
Cancer Epidemiol Biomarkers Prev; 1996 May; 5(5):371-4. PubMed ID: 9162303
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of alpha-difluoromethylornithine as a potential chemopreventive agent: tolerance to daily oral administration in humans.
Creaven PJ; Pendyala L; Petrelli NJ
Cancer Epidemiol Biomarkers Prev; 1993; 2(3):243-7. PubMed ID: 8318877
[TBL] [Abstract][Full Text] [Related]
15. Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration.
Waters GS; Ahmad M; Katsarkas A; Stanimir G; McKay J
Ear Hear; 1991 Apr; 12(2):91-102. PubMed ID: 2065844
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of hepatic arterial infusion using difluoromethylornithine.
Lipton A; Harvey HA; Glenn J; Weidner WA; Strauss M; Miller SE; Taylor JB; White-Hershey D; Barlow JL
Cancer; 1989 Feb; 63(3):433-7. PubMed ID: 2492203
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of alpha-difluoromethylornithine and methyl-GAG.
Splinter TA; Romijn JC
Eur J Cancer Clin Oncol; 1986 Jan; 22(1):61-7. PubMed ID: 3082642
[TBL] [Abstract][Full Text] [Related]
18. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.
Levin VA; Uhm JH; Jaeckle KA; Choucair A; Flynn PJ; Yung WKA ; Prados MD; Bruner JM; Chang SM; Kyritsis AP; Gleason MJ; Hess KR
Clin Cancer Res; 2000 Oct; 6(10):3878-84. PubMed ID: 11051233
[TBL] [Abstract][Full Text] [Related]
19. Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps.
Meyskens FL; Emerson SS; Pelot D; Meshkinpour H; Shassetz LR; Einspahr J; Alberts DS; Gerner EW
J Natl Cancer Inst; 1994 Aug; 86(15):1122-30. PubMed ID: 8028034
[TBL] [Abstract][Full Text] [Related]
20. Cochlear damage and increased threshold in alpha-difluoromethylornithine (DFMO) treated guinea pigs.
Salzer SJ; Mattox DE; Brownell WE
Hear Res; 1990 Jun; 46(1-2):101-12. PubMed ID: 2116404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
